Skip to main content
. 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285

Table 4.

Toxicity during maintenance therapy and supportive agents.

Global Group
(N = 405) 		R-CHOP
(N = 245) 		R-BENDA
(N = 160) 		p
Pneumocystis carinii prophylaxis (maintenance): 165 (45%) 109 (49%) 57 (40%) 0.13
Herpes prophylaxis (maintenance): 113 (31%) 55 (25%) 58 (39%) 0.004
G-CSF during maintenance:
  • -

    No

  • -

    Primary prophylaxis

  • -

    Secondary prophylaxis
312 (87%)
9 (2%)
39 (11%)
200 (91%)
6 (3%)
13 (6%)
112 (79%)
3 (2%)
26 (18%)		 <0.001
Rituximab maintenance: 392 (97%) 237 (97%) 155 (97%) 1
Maintenance discontinuation: 75 (19%) 29 (12%) 46 (30%) <0.001
Causes of discontinuation:
  • -

    Patient/physician decision

  • -

    Toxicity

  • -

    Lymphoma progression
17 (22%)
31 (41%)
28 (27%)
7 (24%)
4 (14%)
18 (62%)
10 (21%)
27 (57%)
10 (21%)		 <0.001
Neutropenia:
  • -

    No

  • -

    Grade 1–2

  • -

    Grade 3–4
286 (77%)
42 (11%)
44 (12%)
190 (84%)
20 (9%)
15 (7%)
96 (65%)
22 (15%)
29 (20%)		 <0.001
Anemia:
  • -

    No

  • -

    Grade 1–2

  • -

    Grade 3–4
324 (88%)
42 (11%)
3 (1%)
196 (88%)
26 (12%)
1 (0.4%)
128 (88%)
16 (11%)
2 (1%)		 0.62
Thrombocytopenia:
  • -

    No

  • -

    Grade 1–2

  • -

    Grade 3–4
331 (89%)
31 (8%)
9 (2%)
199 (88%)
21 (9%)
6 (3%)
132 (91%)
10 (7%)
3 (2%)		 0.66
Infections: 68 (18%) 27 (12%) 41 (28%) <0.001
Severe infections
Hospitalization: 25 (7%) 13 (6%) 12 (8%) 0.4
Second malignancies:
  • -

    Yes

  • -

    No

  • -

    Unknown
29 (7%)
257 (63%)
119 (29%)
16 (6%)
156 (64%)
73 (30%)
13 (8%)
101 (63%)
46 (29%)		 0.82